Alexandria Venture Investments

Hoofprint Biome is a biotechnology company that develops probiotics and natural enzymes to enhance the sustainability of ruminant livestock production. Their products improve cattle health and digestive care by reducing methane emissions, thereby enabling the livestock industry to adopt more sustainable practices through microbiome engineering.

Solu Therapeutics is a precision medicine company developing therapeutics focused on eliminating disease-driving cells. Its platform combines selective small-molecule binders with proprietary antibodies to create bifunctional therapeutics, targeting inflammatory and autoimmune diseases.

Avalo is a plant biology company that employs interpretable machine learning, genomic discovery, and evolutionary theory to expedite the development of new crops tailored for future agricultural needs. Utilizing AI-assisted plant breeding methods, Avalo creates non-GMO products that foster natural biodiversity. Its core technology, a discovery engine, can swiftly identify genetic bases of complex traits even in understudied crops, reducing time and cost significantly compared to traditional methods. This enables Avalo to forecast and enhance crop traits like drought tolerance and nutrient density, adapting agriculture to changing climates.

Meiogenix is a biotechnology company developing breeding technologies to uncover unexplored genetic diversity in organisms, expanding natural biodiversity and enabling the development of products to address global food, climate, sustainability, and industrial challenges. It uses chromosome-editing-based approaches to modulate the frequency of homologous recombination in eukaryotic cells, enabling natural breeding and delivering new products for farmers and industry.

Autoimmunity BioSolutions is a biotechnology company developing innovative solutions for autoimmune diseases, with a focus on multiple sclerosis. Their core technology involves a next-generation immuno-corrective therapy, tailored to a specific genetic subgroup of autoimmune patients. This therapy aims to restore normal immune function by targeting a specific genetic variant (SNP) driving the autoimmune pathology. The company's platform enables targeted modulation of the immune system, offering potential clients a means to correct immune system dysfunction with precision therapies.

Valora Therapeutics, based in San Diego, California, is a biotechnology company focused on the development of innovative biological drugs. It specializes in engineering chimeric antibodies, which are designed to harness the body's immune system to fight cancer and other diseases. The company operates at the pre-clinical stage, working to unlock new mechanisms of immune signaling and activity, with the aim of providing transformative therapies to the healthcare industry.

Jupiter Bioventures is a venture builder company dedicated to de-risking early-stage therapeutic projects. It operates by evaluating opportunities through a specific set of investment criteria and providing initial seed capital to founders. This approach enables the growth of innovative projects in the biotechnology sector, supporting entrepreneurs as they navigate the challenges of early development. By focusing on early-stage initiatives, Jupiter Bioventures aims to foster advancements in therapeutic solutions while minimizing the inherent risks associated with new ventures.

TRexBio is a biotechnology company that leverages cutting-edge computational biology tools, a focus on human tissue, and expertise in immunobiology to develop therapeutics for cancer and inflammatory diseases. Its 'deep biology' discovery engine maps human tissue Treg behavior to disease processes, identifying and characterizing novel targets for therapeutic intervention. The platform supports the development of a portfolio of therapies that modulate the immune system to restore tissue immune homeostasis.

CrossBridge Bio is a biotechnology company specializing in the development of antibody-drug conjugates (ADCs) for cancer treatment. It innovates through its stable dual linker payload technology, aiming to enhance efficacy and safety profiles.

Harpe Bioherbicide Solutions is a Raleigh-based company that provides sustainable weed-management solutions for organic and industrial agriculture. Harpe Bio's technologies deliver natural crop protection by utilizing a variety of plant extracts. The plant extracts serve as a platform that may be tailored to various weed management circumstances. Harpe's herbicide platform can be used alone or in conjunction with any currently marketed herbicide. Harpe's new modes and areas of action will improve synthetic herbicide efficacy, including the reduction of resistant weed populations.

Archon Bio is a biotechnology company that specializes in engineering proteins to enhance therapeutic outcomes. It focuses on creating self-assembling protein antibody nanomaterials, aiming to improve immune modulation and super agonism of the TNF receptor superfamily. By increasing the size and valency of off-the-shelf antibodies, Archon seeks to induce stronger responses, thereby advancing regenerative medicine and cancer treatment.

Leal Therapeutics is a Massachusetts-based company focused on developing innovative therapeutics aimed at addressing significant and unmet needs in central nervous system disorders. By leveraging precision medicine, Leal Therapeutics seeks to provide effective treatment options for patients suffering from various neurological conditions. The company's commitment to advancing therapeutic solutions is reflected in its dedication to improving patient outcomes through targeted interventions.

March Biosciences is a clinical-stage biotechnology company specializing in cell therapies for hematological cancers. It focuses on developing CAR-T cell therapies, with its lead product, MB-105, targeting CD5 in refractory T-cell lymphoma and leukemia. The company's approach involves biologically informed target selection, simplified CAR-T engineering, and a streamlined manufacturing process to ensure cell functionality and consistency.

Passkey Therapeutics is pioneering a new class of medicines, Synergistic Multifunctional Therapeutics (SMThs). It is designed to address complex diseases by targeting rare combinations of proteins that work together.

Founded in 2018, Terray Therapeutics is a biotechnology company based in Pasadena, California. It integrates experimentation and computation to enhance small molecule drug discovery, focusing on intractable diseases. The company's platform generates precise data through a rapid design-make-test-analyze cycle, enabling efficient exploration of chemical space.

Judo Bio is a biotechnology company developing precision therapeutics that target specific cell populations to address genetic diseases. Its innovative receptor targeting approach aims to benefit patients with both common and rare diseases.

858 Therapeutics is a biotechnology company specializing in the discovery of small molecule therapeutics for novel targets in oncology and immunology. The company focuses on innovative approaches such as synthetic lethality, innate immunity, and RNA modulation, with its lead program being a PARG inhibitor currently in early clinical development.

Radiant Biotherapeutics is a pioneering company developing a modular platform for creating multi-valent and multi-specific antibodies. This innovative approach aims to deliver transformative therapies for challenging diseases like cancer, autoimmune disorders, and infections by harnessing the power of avidity and multi-specificity.

AIRNA is a biotechnology company specializing in the development of RNA editing therapies. Its platform enables the creation of therapeutics designed to treat both rare and common diseases, with the goal of improving patients' health.

Bright Peak Therapeutics is a biotechnology company focused on developing a range of immunotherapies aimed at treating cancer and autoimmune diseases. The company specializes in creating immuno-cytokines that possess pharmacological properties enabling tissue and cell-specific targeting of cytokine payloads. This innovative approach is designed to enhance the efficacy of treatments, ultimately improving patient outcomes and quality of life. By leveraging its expertise in cytokine therapeutics, Bright Peak aims to advance the field of immunotherapy and provide effective solutions for challenging medical conditions.

OverT Bio is a biotechnology company focused on developing cell therapies for cancer treatment. The company specializes in identifying and creating novel genetic modifications that empower immune cells to navigate and overcome the obstacles posed by tumors. Through its innovative approach, OverT Bio aims to enhance the effectiveness and durability of immunotherapies, contributing to advancements in cancer identification and treatment within the healthcare sector.

Delphia Therapeutics, headquartered in Boston, USA, is a biotechnology company focused on cancer therapeutics. It operates a laboratory dedicated to studying cancer-driving pathways and developing treatments that target and over-activate specific cancer-linked cell signaling, ultimately leading to the death of tumor cells.

Founded in 2020, Enlaza Therapeutics is a biotechnology company based in La Jolla, California. It specializes in developing covalent protein therapeutics using a novel synthetic biology platform, aiming to deliver efficacious and safer treatments with prolonged effects and minimal systemic exposure.

5Metis is a pure-play discovery company focused on crop health. It emerged from the combination of the Boragen and AgriMetis platforms, integrating boron-based small-molecule discovery with synthetic biology to identify new modes of action for crop protection and health. The company aims to deliver novel modes of action not currently available in the agrichemical industry, enabling farmers to improve crop protection and overall crop health through targeted solutions.

Clasp Therapeutics develops precision oncology platforms to identify neoantigens from driver mutations in hard-to-treat cancers. Its technology enables the creation of targeted therapies that selectively bind to HLA-presented peptides, allowing for precise destruction of cancer cells across various tumor types.

Umaro Foods focuses on creating a sustainable plant-based protein derived from ocean-farmed seaweed. The company aims to provide an alternative to traditional animal products by offering nutritious and flavorful food options, including crispy and umami-rich bacon alternatives. By leveraging seaweed farming, Umaro seeks to promote a more humane treatment of animals while also supporting environmental sustainability. The innovative approach positions seaweed as a viable and scalable source of protein, which can surpass traditional soy production, contributing to a thriving planet.

Advanced Animal Diagnostics, Inc. specializes in the research, development, and commercialization of on-farm diagnostic tools aimed at the early detection of subclinical mastitis in dairy cows. Founded in 2001 and based in Durham, North Carolina, the company offers innovative products such as the QScout Farm Lab, an analyzer system that detects infections before visible symptoms occur, and the QScout Milk Leukocyte Differential rapid test, which identifies and differentiates leukocytes in milk to facilitate early mastitis detection. Additionally, Advanced Animal Diagnostics provides the QuickSmear slide for animal research and the SCC+ System for timely mastitis diagnosis. The company's solutions focus on enhancing the management of disease states and improving the reproductive, nutritional, and overall health of production animals, serving veterinarians and livestock producers to promote healthier and more productive animal care.

Elo Life Systems is a biotechnology company dedicated to enhancing human health through innovative food solutions. It aims to bridge gaps between food, agriculture, and health by partnering with stakeholders across the food systems value chain. Elo employs precision breeding technologies, genomics, data analytics, machine learning, and gene editing capabilities to develop healthier, more sustainable food options.

Tr1x specializes in developing cellular therapies aimed at treating autoimmune disorders. The company employs its proprietary platform to create innovative cell therapy products designed to reset the immune system and restore balance, thereby promoting long-term tolerance.

Remix Therapeutics Inc. is a biotechnology company focused on the research and development of innovative small-molecule therapies aimed at reprogramming ribonucleic acid (RNA) processing to treat various diseases. Founded in 2018 and based in Cambridge, Massachusetts, the company utilizes its proprietary biology platform to discover and develop RNA processing modulators that target previously undruggable disease drivers. Through its REMseq platform, Remix Therapeutics validates therapeutic targets and optimizes chemical compounds, facilitating the identification of patterns in RNA processing. This approach allows for the modulation of gene expression, enabling healthcare practitioners to address the underlying causes of diseases by correcting, enhancing, or eliminating gene messages at their source.

CIBO Technologies, Inc. is a company that specializes in developing software products to model and simulate agricultural ecosystems, aimed at enhancing sustainable practices in agriculture. Its key offerings include Continuum DB, a distributed database for spatio-temporal modeling; BarnCAT, a computational agronomy toolkit; WhetherRain, an integrated weather simulation tool; and DirtPatch, a platform for environmental reconstruction. Additionally, CIBO provides TerraFarm for planetary-scale simulations and the Land Intelligence platform, which generates insights on agricultural parcels while offering access to publicly available data for various stakeholders in the agriculture sector. The company's solutions are designed to support a wide range of crops and serve multiple industries, including farm services, agribusiness, and sustainability. Founded in 2014 and based in Cambridge, Massachusetts, with additional offices in Saint Louis, East Lansing, and Minneapolis, CIBO aims to advance food system resilience and improve grower outcomes in the face of climate change.

Tome Biosciences is a biotechnology company specializing in programmable gene insertion technology. Utilizing CRISPR, the company develops methods to insert genetic sequences of any size at various locations within any genome. This innovative approach aims to enhance the ability to detect and eliminate deoxyribonucleic acid from similar bacteriophages during infections. By advancing cell and genome engineering, Tome Biosciences seeks to provide effective therapeutic solutions for patients, paving the way for significant advancements in genetic medicine.

Ability Biotherapeutics develops tailored immune-modulating biotherapeutics to address unmet medical needs in patients with cancer and autoimmune diseases, utilizing advanced AI technology.

Alto Neuroscience is a clinical-stage biopharmaceutical company focused on redefining psychiatry through the integration of patient neurobiology into the drug development process. Utilizing an AI-enabled biomarker platform, the company combines diverse information about patients' brain activity and behavior to create personalized and effective treatment options. Alto Neuroscience is developing several clinical assets, including ALTO-100, ALTO-202, ALTO-101, and ALTO-300, primarily targeting depressive disorders and schizophrenia, identified through independent brain-based biomarkers. By moving away from traditional trial-and-error methods, the company aims to align its innovative therapies with the specific needs of patients, ultimately improving the management of mental health conditions.

Triveni Bio is a biotechnology company specializing in the development of novel antibody therapies for immunological and inflammatory disorders. The company employs a genetics-driven precision medicine approach to identify patients most likely to respond to its treatments, aiming to accelerate drug development and improve the effectiveness and safety of therapies.

DEKA Biosciences is an early-stage biotechnology company focused on developing next-generation cytokine therapeutics aimed at treating cancer and inflammatory diseases. The company creates therapies with disease-specific applications that enhance patient outcomes by optimizing pharmacokinetics and pharmacodynamics through the targeted delivery of dual and complementary cytokines to affected tissues or cells. This innovative approach seeks to provide patients with curative treatment options for various conditions, including cancer, autoimmune disorders, and infectious diseases.

Arialys Therapeutics is a pre-clinical stage biotechnology company that specializes in neuroscience, particularly in the development of precision medicines aimed at blocking pathogenic autoantibodies in the brain. The company investigates the role of the immune system in central nervous system (CNS) health and disease, focusing on the characterization and prevalence of pathogenic auto-antibody activity. Arialys Therapeutics aims to provide advanced therapies for various CNS disorders, including neuropsychiatric conditions linked to autoimmune diseases, thereby contributing to the healthcare industry's efforts to address complex neurological challenges.

Georgiamune is an immunotherapy company that develops oncology-focused treatments. It advances next-generation immunotherapies and homeostatic therapies aimed at cancer and autoimmune diseases. The company's approach targets immune signaling pathways to reprogram the immune system and restore immune homeostasis, helping patients fight cancer and autoimmune conditions.

Solu Therapeutics is a precision medicine company developing therapeutics focused on eliminating disease-driving cells. Its platform combines selective small-molecule binders with proprietary antibodies to create bifunctional therapeutics, targeting inflammatory and autoimmune diseases.

AltPep Corp is a biomedical startup that specializes in diagnosing and treating amyloid diseases, which are known for their complexity and difficulty in management. The company has developed a proprietary peptide-based platform designed to diagnose and neutralize toxic precursors associated with these diseases. This innovative approach includes diagnostic, therapeutic, and anti-biofilm applications, particularly aimed at the early detection of toxic oligomers in Alzheimer's disease through a soluble oligomer binding assay. By focusing on early detection and effective treatment strategies, AltPep aims to enhance healthcare outcomes related to amyloid diseases, ultimately improving human health.

Bitterroot Bio specializes in developing innovative therapies for cardiovascular disease by harnessing the power of immunotherapy.

Myeloid Therapeutics is an immunology company dedicated to leveraging innovative technologies to harness the potential of myeloid cells for the treatment of cancer and other diseases. The company has developed the ATAK platform, which focuses on reprogramming innate immune cells to enhance their ability to target and eliminate cancerous cells. Initially, Myeloid Therapeutics is advancing a cell therapy program aimed at treating T cell lymphoma, as well as a primed monocyte strategy for glioblastoma. The versatility of the ATAK platform allows for scalability across various treatment modalities and disease areas, facilitating collaboration with partners to expand its applications in the field of immunotherapy.

Ten63 Therapeutics, Inc. is a biotechnology company based in Chapel Hill, North Carolina, focused on developing potent therapeutics for medically validated yet undruggable targets. Founded in 2017, the company utilizes its innovative platform, COPPER, which combines machine learning-based computational chemistry with advanced physical modeling to explore an extensive chemical space. This approach allows Ten63 Therapeutics to discover novel drug candidates for some of the most lethal diseases by employing proprietary algorithms for scaffold redesign and optimizing chemical design. By integrating these technologies, the company aims to produce durable therapies and improve drug resistance prediction, ultimately addressing challenges in drug development for previously intractable targets.

Radiant Biotherapeutics is a pioneering company developing a modular platform for creating multi-valent and multi-specific antibodies. This innovative approach aims to deliver transformative therapies for challenging diseases like cancer, autoimmune disorders, and infections by harnessing the power of avidity and multi-specificity.

Harpe Bioherbicide Solutions is a Raleigh-based company that provides sustainable weed-management solutions for organic and industrial agriculture. Harpe Bio's technologies deliver natural crop protection by utilizing a variety of plant extracts. The plant extracts serve as a platform that may be tailored to various weed management circumstances. Harpe's herbicide platform can be used alone or in conjunction with any currently marketed herbicide. Harpe's new modes and areas of action will improve synthetic herbicide efficacy, including the reduction of resistant weed populations.

TORL BioTherapeutics is a clinical-stage biopharmaceutical company dedicated to developing innovative, antibody-based therapies aimed at enhancing the lives of cancer patients. The company specializes in antibody-drug conjugates and other biologics, focusing on oncologic diseases with significant unmet medical needs. TORL BioTherapeutics employs a strategy that involves target identification and early discovery work, allowing them to selectively advance drug programs through novel licensing agreements. This approach enables their researchers to develop proprietary drugs with unique and optimized profiles, contributing to the advancement of cancer treatment options.

Function Oncology is a precision medicine company focused on transforming cancer treatment through its innovative CRISPR-powered personalized functional genomics platform. This platform enables the identification of therapeutic opportunities tailored to individual patients, allowing for a deeper understanding of cancer at a patient-specific level. By leveraging advanced genomic techniques, Function Oncology aims to develop targeted cancer therapies that address the unique characteristics of each patient's disease, ultimately advancing the future of cancer care.

Tiamat Sciences is a start-up focused on producing affordable, animal-free growth factors and biomolecules through innovative plant-based bioreactors. Utilizing proprietary technology, the company manufactures a diverse array of high-value proteins, including antigens and growth factors, achieving significant cost reductions—up to 10 times lower than traditional methods, with potential for further reductions at scale. This technology not only enhances production efficiency but also supports ecological sustainability by providing plant-based alternatives to animal-derived materials in the pharmaceutical industry. Tiamat's approach increases the safety and speed of production, positioning it as a strategic partner for scaling operations in burgeoning sectors such as cellular agriculture and gene therapy. The low capital investment required for facility setup makes Tiamat an attractive option in a market poised for substantial growth.

Ring Therapeutics is a biotechnology company developing gene therapies using Anellovector, a redosable and targetable DNA therapy platform based on the biology of the human commensal virome. The platform aims to address limitations of current DNA therapies, including limited tissue access, inability to redose, potential genomic integration, and tolerability concerns. Founded in 2017 and based in Cambridge, Massachusetts, Ring Therapeutics was established by Flagship Pioneering to pursue a multi-product platform. It focuses on discovering and developing Anellovector therapeutics to unlock the full potential of gene therapy, moving beyond gene replacement to a broader set of modalities and mechanisms. The approach targets disease sites with tissue and cellular specificity, aiming to treat conditions across genetic disorders, ophthalmology, oncology, and metabolic disorders and to expand therapeutic options for previously inaccessible diseases.

Paratus Sciences focuses on advancing human health and health security by studying the biology of bats. It integrates cell biology, genomics, informatics, and large-scale data inputs to compare disease resistance patterns in bats with those in humans, aiming to develop therapeutics that mimic bats' adaptations.

Garuda Therapeutics is a biotechnology company focused on developing off-the-shelf hematopoietic stem cell therapies aimed at treating life-threatening blood, bone marrow, immune, and metabolic diseases. The company is dedicated to eliminating the reliance on donor or patient cells for blood stem cell transplants. Utilizing advanced technologies, including zebrafish, mice, and human-induced pluripotent stem cells, Garuda Therapeutics conducts research to clone and analyze novel genes and mechanisms critical for blood formation. This innovative approach is designed to provide patients with consistent, durable, and HLA-compatible transgene-free blood stem cell therapies, offering rapid and broad access to life-saving treatments.

IgGenix, Inc. is a biotechnology company focused on developing an innovative antibody therapeutics platform aimed at treating food and non-food allergies, as well as other severe allergic conditions. The company specializes in isolating and transforming allergen-specific IgE antibodies into IgG antibodies, which are designed to alleviate and potentially prevent allergic reactions. By capturing and analyzing rare human B cells that express allergen-binding antibodies, IgGenix engineers these antibodies to incorporate immune-modulating activities derived from the IgG class, thereby enhancing their ability to suppress allergic responses. Founded in 2019 and based in South San Francisco, California, IgGenix is dedicated to addressing the challenges posed by life-threatening allergic reactions through its advanced therapeutic solutions.

Melonfrost is a biotechnology company located in Brooklyn, New York. It specializes in developing a clinical research platform aimed at optimizing biological strains by addressing operational bottlenecks. The company employs a combination of machine learning, proprietary artificial intelligence, and advanced hardware to facilitate real-time cell evolution. This innovative approach enables Melonfrost to explore the biological landscape effectively and implement advancements in robotics, sensing, fluidics, and environmental control. By streamlining scientific labor processes, Melonfrost significantly reduces the time required to bring bioproducts to market, thereby enhancing the efficiency and effectiveness of biotechnological innovations.

Developer of innovative pharmaceutical platforms and therapies focused on treating central nervous system disorders. Dantari specializes in researching and developing small and large molecule therapeutics that can cross the blood-brain barrier, aiming to rapidly advance treatments for meaningful patient improvement.

Cajal Neuroscience is a biotechnology company dedicated to discovering novel targets and therapeutics for neurodegeneration. It integrates human genetics, functional genomics, and advanced microscopy to accelerate drug discovery in this field.

Rezo Therapeutics is a biotechnology company that focuses on pioneering the integrated mapping of disease networks to develop precision therapeutics. Utilizing its proprietary Sequence to Systems to Drugs (SSD) platform, Rezo combines proteomics, genetics, structural biology, chemistry, and bioinformatics to create comprehensive maps of molecular disease networks. This innovative approach enables oncologists and researchers to identify novel targets and therapies with greater clarity and precision than traditional drug discovery methods. Initially concentrating on oncology, Rezo Therapeutics plans to expand its therapeutic focus through collaborations and partnerships, aiming to address a wide range of diseases.

Haystack Oncology is an oncology company that specializes in advanced liquid biopsy diagnostic technology aimed at improving cancer treatment strategies and patient outcomes. The company utilizes state-of-the-art circulating tumor DNA detection methods to enhance the diagnosis of minimal residual disease, allowing for more informed therapy decision-making. By analyzing tumor-specific markers in blood samples, Haystack Oncology's technology provides high sensitivity for early detection of recurrent disease, thereby enabling healthcare teams to effectively manage cancer treatment. The company's innovative approach seeks to transform how cancer is monitored and treated, ultimately benefiting patients through improved diagnostic accuracy and treatment effectiveness.

Matchpoint Therapeutics is a biotechnology company focused on developing precision covalent medicines aimed at transforming the treatment of immune diseases and other serious illnesses. Utilizing its proprietary Advanced Covalent Exploration (ACE) platform, the company combines advanced chemoproteomics, machine learning, and the evolution of covalent chemistry libraries to enhance the discovery process. This innovative approach allows for deeper probing of the proteome to identify new binding sites on disease-causing proteins. Matchpoint is building an emerging pipeline of novel covalent medicines, with an initial emphasis on immunology.

Tavros Therapeutics is a biotechnology company based in Durham, North Carolina, focused on discovering and developing therapies for cancer. Founded in 2019, the company aims to advance oncology treatments by identifying vulnerabilities within tumors. This approach allows for targeted drug combinations, potentially improving outcomes for patients with oncological diseases.

Capstan Therapeutics specializes in developing innovative therapeutics using precision cell engineering for various diseases with unmet clinical needs.

Novome Biotechnologies, Inc. is a biotechnology company specializing in the engineering of gut bacteria to create innovative therapies for chronic diseases. Established in 2015 and located in South San Francisco, California, Novome has developed a pioneering platform for the controlled colonization of the gut with genetically engineered microbial medicines (GEMMs). This platform allows for the precise delivery of therapeutic activities aimed at treating conditions such as hyperoxaluria, with a focus on creating a bacterial strain that can degrade oxalate to help prevent kidney stone formation. The company is also expanding its synthetic biology capabilities to explore additional therapeutic indications, aiming to improve long-term health outcomes for patients through its living therapeutics.

Senda Biosciences, founded in 2017 by David Kolesky, Ignacio Martinez, and John Casey in Cambridge, Massachusetts, focuses on developing therapeutic applications for innovative treatments of human diseases. The company specializes in studying the molecular relationships between bacterial, botanical, and human cells to understand how these interactions influence health and disease. By gaining insights into these interspecies connections, Senda Biosciences aims to create novel categories of medicines and delivery methods, providing medical professionals with new tools to combat various illnesses.

Ozette Technologies specializes in digitizing biological data using machine learning to provide a comprehensive view of an individual's immune system. This enables accelerated discovery and development of therapies and diagnostics.

Cartography Biosciences specializes in developing precision cancer immunotherapies. It employs single-cell analysis to identify novel targets for Chimeric Antigen Receptor T-cell (CAR-T) therapies, aiming to enhance safety and efficacy.

DEM BioPharma is an immuno-oncology company focused on developing innovative therapies to combat cancer by harnessing the innate immune system. The company is pioneering a platform dedicated to creating next-generation macrophage immunotherapies, which aim to activate macrophages and immune phagocytes to effectively target and eliminate tumors. By researching and targeting specific signals on both cancer cells and macrophages, DEM BioPharma seeks to provide healthcare researchers with advanced treatment options that enhance the body's ability to fight cancer.

Dren Bio is a biotechnology company that specializes in protein engineering technologies aimed at depleting pathogenic cells, protein aggregates, and other disease-causing agents. The company operates under a holding business model, developing a diverse portfolio of projects that function as stand-alone assets. Dren Bio's platform is designed to address a range of health conditions, including hematologic neoplasms, solid tumors, autoimmune disorders, and diseases associated with protein aggregation. By focusing on innovative protein-based technologies, Dren Bio enables healthcare professionals to manage and treat various serious diseases more effectively.

Pleno is a biotechnology company based in San Diego, California, founded in 2017. The company specializes in accelerating disease diagnosis and treatment through its innovative multi-omic platform. This technology is designed for biological target detection in clinical testing and biomedical research, offering capabilities for monitoring minimal residual disease and early multi-cancer screening. Pleno's platform detects a wide range of analytical targets, including DNA, RNA, and protein biomarkers, with exceptional speed and precision. By utilizing advanced microfluidics, the company automates all aspects of sample preparation and analysis, thereby enhancing healthcare providers' access to diverse health monitoring technologies.

Remix Therapeutics Inc. is a biotechnology company focused on the research and development of innovative small-molecule therapies aimed at reprogramming ribonucleic acid (RNA) processing to treat various diseases. Founded in 2018 and based in Cambridge, Massachusetts, the company utilizes its proprietary biology platform to discover and develop RNA processing modulators that target previously undruggable disease drivers. Through its REMseq platform, Remix Therapeutics validates therapeutic targets and optimizes chemical compounds, facilitating the identification of patterns in RNA processing. This approach allows for the modulation of gene expression, enabling healthcare practitioners to address the underlying causes of diseases by correcting, enhancing, or eliminating gene messages at their source.

Pheast Therapeutics is a cancer immunotherapy company developing macrophage-targeted therapies and innate immune checkpoint inhibitors to engage the body's innate immune response against cancer. The company focuses on agents that enhance macrophage phagocytosis and tumor cell elimination, including antibodies targeting CD24 to boost macrophage activity. Founded in 2020 and headquartered in Palo Alto, California, Pheast aims to offer innovative oncology treatments that complement existing therapies and improve patient outcomes.

Umaro Foods focuses on creating a sustainable plant-based protein derived from ocean-farmed seaweed. The company aims to provide an alternative to traditional animal products by offering nutritious and flavorful food options, including crispy and umami-rich bacon alternatives. By leveraging seaweed farming, Umaro seeks to promote a more humane treatment of animals while also supporting environmental sustainability. The innovative approach positions seaweed as a viable and scalable source of protein, which can surpass traditional soy production, contributing to a thriving planet.

Affini-T Therapeutics is a biotechnology company developing T-cell therapies for patients suffering from cancer. Affini-T uses a validated platform to select high-affinity T cell receptors specific to oncogenic mutations to pioneer cutting-edge solid tumor therapies. Affini-T leverages gene editing and synthetic biology to engineer novel T-cell therapies designed to eradicate tumors.

Eclipse Bioinnovations is an RNA genomics company focused on advancing RNA medicines and scientific discovery through platform technologies that map RNA binding proteins, RNA interactions, and transcript features. Building on UC San Diego research, it offers eCLIP-based tools such as eCLIP-RBP, miR-eCLIP, and m6A-eCLIP, End-Seq for 5' and 3' ends, and FLI-Seq to streamline CRISPR library prep. Products are provided as services and kits for biopharma companies and academic researchers, with customized solutions for clients. The company also develops cell-free genomics technologies that improve crosslinking and immunoprecipitation to identify RNA binding protein targets, accelerating research and drug development across diseases.

TRexBio is a biotechnology company that leverages cutting-edge computational biology tools, a focus on human tissue, and expertise in immunobiology to develop therapeutics for cancer and inflammatory diseases. Its 'deep biology' discovery engine maps human tissue Treg behavior to disease processes, identifying and characterizing novel targets for therapeutic intervention. The platform supports the development of a portfolio of therapies that modulate the immune system to restore tissue immune homeostasis.

Creyon Bio is a pre-clinical stage company focused on advancing drug development through a data-driven methodology. It specializes in engineering RNA-based medicines and their components by creating proprietary datasets that inform advanced machine learning models. This innovative approach enables the rapid identification of design rules and engineering principles necessary for the development of safe and effective oligonucleotide-based medicines. By leveraging these insights, Creyon Bio aims to improve the efficiency of the drug development process, ultimately contributing to cost savings in the healthcare sector while catering to diverse patient populations.

Founded in 2018, Terray Therapeutics is a biotechnology company based in Pasadena, California. It integrates experimentation and computation to enhance small molecule drug discovery, focusing on intractable diseases. The company's platform generates precise data through a rapid design-make-test-analyze cycle, enabling efficient exploration of chemical space.

Harpe Bioherbicide Solutions is a Raleigh-based company that provides sustainable weed-management solutions for organic and industrial agriculture. Harpe Bio's technologies deliver natural crop protection by utilizing a variety of plant extracts. The plant extracts serve as a platform that may be tailored to various weed management circumstances. Harpe's herbicide platform can be used alone or in conjunction with any currently marketed herbicide. Harpe's new modes and areas of action will improve synthetic herbicide efficacy, including the reduction of resistant weed populations.

Avalo is a plant biology company that employs interpretable machine learning, genomic discovery, and evolutionary theory to expedite the development of new crops tailored for future agricultural needs. Utilizing AI-assisted plant breeding methods, Avalo creates non-GMO products that foster natural biodiversity. Its core technology, a discovery engine, can swiftly identify genetic bases of complex traits even in understudied crops, reducing time and cost significantly compared to traditional methods. This enables Avalo to forecast and enhance crop traits like drought tolerance and nutrient density, adapting agriculture to changing climates.

Ambys Medicines, Inc. is a biotechnology company based in Redwood City, California, focused on discovering and developing innovative therapies for severe liver diseases. Founded in 2016, Ambys aims to transform the lives of individuals suffering from liver conditions by creating advanced gene, drug, and cell therapies. The company is dedicated to restoring liver function, halting the progression of liver disease, and addressing the serious complications associated with liver failure. Through its regenerative medical therapies, Ambys seeks to provide relief to patients with chronic liver diseases, ultimately improving their quality of life.

Meiogenix is a biotechnology company developing breeding technologies to uncover unexplored genetic diversity in organisms, expanding natural biodiversity and enabling the development of products to address global food, climate, sustainability, and industrial challenges. It uses chromosome-editing-based approaches to modulate the frequency of homologous recombination in eukaryotic cells, enabling natural breeding and delivering new products for farmers and industry.

NextVivo is a biotechnology company developing an immune organoid technology platform. This platform aims to transform drug development by accelerating the creation of safer, more effective therapies. It achieves this by generating and testing therapies in human-derived models that mimic the body's natural immune response.

Founded in 2018, Fountain Therapeutics develops cellular model-based therapeutics targeting age-related diseases. It employs an AI-driven platform for identifying novel targets and potential treatments.

GeneCentric Diagnostics is engaged in the development and commercialization of molecular diagnostic tests aimed at assisting oncologists and patients in cancer treatment. The company has established two primary platform technologies: The Lung Subtype Platform (LSP), which classifies lung cancer patients into specific subtypes to guide therapeutic choices, and the Hypoxia Signature, designed to identify patients likely to benefit from anti-angiogenesis therapies. The LSP has been licensed to Laboratory Corporation of America Holdings and is available as HistoPlusSM: Lung Cancer through its Integrated Oncology division. GeneCentric's innovative partnership model facilitates the translation of significant cancer research into diagnostics that are clinically adopted by pathologists and clinicians. Incorporated in 2011 and located in Durham, North Carolina, GeneCentric aims to enhance treatment outcomes by enabling more precise targeting of therapeutic compounds based on tumor biology.

Parthenon Therapeutics is inventing a novel class of anti-cancer therapies that reprogram the tumor microenvironment (TME). The interplay between cancer cells and their surrounding microenvironment is relevant in drug development as manycancers use the TME to build barriers that shield immune system attack. One approach, PRTH-101, breaks these barriers to overcome recalcitrant cancers. Based on research, the company is designing a portfolio of drug candidates to treat the right patients at the right time.

Nitrase Therapeutics is a biopharmaceutical company developing therapies against a novel class of enzymes called nitrases, initially focusing on Parkinson’s disease. Its proprietary platform enables the identification and targeting of these enzymes to potentially slow or halt disease progression.

DEKA Biosciences is an early-stage biotechnology company focused on developing next-generation cytokine therapeutics aimed at treating cancer and inflammatory diseases. The company creates therapies with disease-specific applications that enhance patient outcomes by optimizing pharmacokinetics and pharmacodynamics through the targeted delivery of dual and complementary cytokines to affected tissues or cells. This innovative approach seeks to provide patients with curative treatment options for various conditions, including cancer, autoimmune disorders, and infectious diseases.

Soli Organic is an indoor farming company that grows and supplies fresh organic culinary herbs to grocery stores year-round. It uses a vertically integrated approach to produce living organic plants with fresh-cut leaves, including lime leaves, rosemary, chives, and arugula, grown regionally to emphasize freshness and sustainability. By delivering a steady, locally produced supply of herbs, the company aims to provide high-quality, flavorful products to retailers and their customers.

Immunai develops an AI-based immune profiling platform for drug discovery, diagnosis, and treatment. It offers multi-omic single-cell genomics with machine learning algorithms, enabling high-resolution profiling of the immune system at scale. Immunai partners with academic institutions and biopharmaceutical companies to accelerate research and development in immunology.

Mozart Therapeutics is a biotechnology company specializing in the development of disease-modifying therapies for autoimmune and inflammatory diseases. It focuses on creating first-in-class CD8 Treg modulators to restore long-term immune balance and prevent progressive damage caused by autoreactive immune responses.

Crop Enhancement LLC is an early-stage specialty materials company based in San Jose, California, founded in 2011. The company focuses on developing innovative anchoring and controlled-release formulation technologies for agricultural chemicals. Its advanced agrochemical formulations utilize environmentally friendly chemistry to enhance crop yields and profitability while minimizing the reliance on synthetic pesticides. Crop Enhancement's products include proprietary films that modify plant surfaces, improving resistance to pests and diseases. This approach not only supports sustainable farming practices but also enables precise delivery of active ingredients and fertilizers, ultimately benefiting growers through increased efficiency and reduced chemical use.

BIOMILQ develops lab-grown human milk ingredients from cultured mammary cells to support infant nutrition. Founded in 2020 and based in Durham, North Carolina, the company is women-owned and science-led, building a mammary biomanufacturing platform to produce bioauthentic human milk ingredients for early-life nutrition. The platform combines human mammary cells with a scalable manufacturing process to create milk ingredients that promote gut, immune, and brain development, offering families a nutritious and sustainable option for feeding babies.

IpiNovyx Bio is a biopharmaceutical company focused on creating a novel platform of immunoproteasome-modulating therapeutics aimed at improving the treatment of autoimmune and inflammatory diseases. The company's innovative approach involves developing inhibitors that selectively target the immunoproteasome, which plays a critical role in regulating specific immune cell types. By modulating these immune responses, IpiNovyx Bio seeks to enable patients to recover more effectively from their conditions and enhance their overall health.

Kytopen Corp., founded in 2017, develops proprietary Flowfect™ technology for non-viral delivery of molecules into hard-to-transfect immune cells. Its platform combines microfluidics and automation to facilitate efficient cell engineering.

Acrigen Biosciences is focused on advancing gene editing technologies to enhance the safety and efficiency of CRISPR-Cas based systems. Founded in 2019 and headquartered in Berkeley, California, the company develops precision gene editing solutions aimed at producing effective and safe in vivo drug therapies for various diseases. Acrigen's innovations include Acro proteins that regulate the CRISPR-Cas gene editing process, along with a bioinformatics discovery software platform designed to identify suitable CRISPR systems for human therapeutic applications. By improving anti-CRISPR proteins and optimizing genetic therapies, Acrigen aims to contribute significantly to the field of medicine and the treatment of debilitating conditions.

ROME Therapeutics, Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing innovative therapies for cancer and autoimmune diseases. Founded in 2019, the company utilizes the repeatome, which encompasses extensive segments of genetic material previously regarded as "junk DNA," to identify new drug targets and advance multiple discovery programs. ROME Therapeutics has assembled a team of experts in oncology, immunology, virology, and machine learning to drive its research and development efforts, aiming to harness this uncharted area of biology for effective treatments. Through its work, ROME seeks to provide healthcare professionals with powerful new options for addressing complex medical challenges.

Lycia Therapeutics operates as a biotechnology company focused on discovering and developing first-in-class therapeutics using its proprietary Lysosomal Targeting Chimeras (LYTACs) platform. This platform enables the degradation of extracellular and membrane-bound proteins associated with challenging-to-treat diseases like cancer and autoimmune disorders, aiming to provide effective treatments for patients.

Disc Medicine is a clinical-stage biopharmaceutical company focused on developing innovative treatments for patients with severe hematologic disorders. Its pipeline includes therapies targeting erythropoietic porphyrias, Diamond-Blackfan Anemia, anemia of myelofibrosis and chronic kidney disease, as well as polycythemia vera.

Asher Biotherapeutics, Inc. is a biotechnology company based in South San Francisco, California, founded in 2019. The company specializes in the development of immunotherapy drugs aimed at effectively treating cancer. Its innovative therapies are designed to enhance the immune system's ability to target and eliminate cancer cells while minimizing side effects. This focus allows healthcare providers to deliver effective treatments to patients in a shorter timeframe, aiming to improve overall outcomes in cancer care.

Humacyte specializes in developing human tissue-based products for regenerative medicine and vascular surgery. It creates acellular extracellular matrices using banked vascular smooth muscle cells, which are then decellularized to eliminate rejection risks. These matrices serve as off-the-shelf tissue-engineered grafts for patients requiring vascular repair or replacement.

eFFECTOR Therapeutics, Inc. is a clinical-stage biotechnology company based in San Diego, California, that specializes in the development of selective translation regulators for the treatment of cancer and other serious diseases. Founded in 2012, the company is pioneering a new class of oncology drugs known as selective translation regulator inhibitors (STRIs). These drug candidates specifically target the eIF4F complex and its associated kinase, MNK 1/2, which play critical roles in protein synthesis and are linked to prominent cancer signaling pathways such as PI3K-AKT and RAS-MEK. eFFECTOR's products aim to inhibit pathways that drive tumor growth, survival, and immune evasion by regulating the expression of oncoproteins and immunosuppressive proteins. The lead candidate, tomivosertib, is currently being evaluated in a Phase 2b trial for non-small cell lung cancer in combination with pembrolizumab. Additionally, zotatifin, an inhibitor of eIF4A, is undergoing dose-escalation in a Phase 1/2 trial, with further expansion cohorts anticipated. The company also collaborates with Pfizer to advance inhibitors targeting eIF4E.

Thryv Therapeutics is a precision medicine company focused on developing innovative therapeutics for Long QT Syndrome and other arrhythmias. The company employs a precision medicine approach to address both genetic and drug-induced long QT syndrome, as well as atrial fibrillation and treatment-resistant cancers. Thryv Therapeutics specializes in creating potent and selective inhibitors of Serum Glucocorticoid Inducible Kinase, aiming to provide therapies that can significantly reduce the risk of sudden cardiac death and enhance the quality of life for patients affected by these serious conditions.